Repros Therapeutics is a development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health.
http://ir.reprosrx.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.8 seconds
PAGES IN
THIS WEBSITE
6
SSL
EXTERNAL LINKS
6
SITE IP
206.200.251.19
LOAD TIME
0.813 sec
SCORE
6.2
Repros Therapeutics Inc. - Investor Relations | ir.reprosrx.com Reviews
https://ir.reprosrx.com
Repros Therapeutics is a development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health.
ir.reprosrx.com
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis (NASDAQ:RPRX)
http://ir.reprosrx.com/releasedetail.cfm?ReleaseID=1004888
Laquo; Previous Release. Next Release ». December 19, 2016. Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex in the Treatment of Endometriosis. THE WOODLANDS, Texas. Dec 19, 2016. Nasdaq:RPRX) today announced it has requested a meeting to discuss Phase 3 requirements for the development of Proellex (telapristone acetate) for the treatment of endometriosis. The Company anticipates a meeting will be scheduled during the first half of 2017. Or at www.sec.gov.
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids (NASDAQ:RPRX)
http://ir.reprosrx.com/releasedetail.cfm?ReleaseID=1003826
Laquo; Previous Release. Next Release ». December 12, 2016. Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex in the Treatment of Symptomatic Uterine Fibroids. Focus on oral formulation. THE WOODLANDS, Texas. Dec 12, 2016. The Company has completed studies on both oral and vaginal delivery and will propose further development of the oral form of the drug. The objective of the meeting with the. The current formulation of Proellex allows for continuous dosing for up to 18 weeks ...
Repros Therapeutics Inc. - Investor Relations
http://ir.reprosrx.com/index.cfm
Board of Directors and Management. Events, Presentations and Webcasts. Repros in the News. Events, Presentations and Webcasts. Repros in the News. 12:01 PM ET on Mar 7, 2017. Delayed at least 20 minutes. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective. Feb 2, 2017. Repros Announces New CEO. Jan 30, 2017. View all releases ».
Repros Therapeutics Inc. - Press Releases
http://ir.reprosrx.com/releases.cfm
Board of Directors and Management. Events, Presentations and Webcasts. Repros in the News. Events, Presentations and Webcasts. Repros in the News. 12:01 PM ET on Mar 7, 2017. Delayed at least 20 minutes. Repros Announces New CEO. Feb 2, 2017. FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex in the Treatment of Uterine Fibroids. Jan 30, 2017. Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex in the Treatment of Endometriosis. Dec 19, 2016.
Repros Therapeutics Inc. - SEC Filings
http://ir.reprosrx.com/sec.cfm
Board of Directors and Management. Events, Presentations and Webcasts. Repros in the News. Events, Presentations and Webcasts. Repros in the News. 12:01 PM ET on Mar 7, 2017. Delayed at least 20 minutes. Mar 2, 2017. Feb 15, 2017. Feb 15, 2017. Cain, daniel f. Feb 15, 2017. Masterson, nola e. Feb 15, 2017. Feb 15, 2017. Amended statement of beneficial ownership. Feb 14, 2017. Feb 13, 2017. Feb 3, 2017. Feb 2, 2017. Jan 30, 2017. Dec 19, 2016. Dec 12, 2016. Dec 9, 2016. Dec 7, 2016. Masterson, nola e.
TOTAL PAGES IN THIS WEBSITE
6
Remy - Investors Overview
Stock Quote and Chart. 160; 0.11. Data as of 08/17/15 4:00 pm ET. Minimum 20 minute delay. August 13, 2015. Remy Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Pending Acquisition Of Remy By BorgWarner. August 03, 2015. Remy International, Inc. Announces Second Quarter 2015 Results. July 30, 2015. Remy International, Inc. Announces Declaration of Dividend on Common Stock; Cancels 2nd Quarter Earnings Conference Call. There are currently no events scheduled.
Renesola - Investors - Investor Home
Stock Quote and Chart. Founded in 2005, and listed on the New York Stock Exchange in 2008, ReneSola (NYSE:SOL) is an international leading brand and technology provider of green energy products. Leveraging its global presence, expansive OEM and sales network, Renesola is well positioned to provide its highest quality green energy products and on-time services for EPC, installers, and green energy projects around the world. For more information, please visit www.renesola.com. Tel: 86-21-62809180 ext 105.
Investor Relations :: Rennova Health, Inc. (RNVA)
Rennova Health Provides Outlook for 2017. January 5, 2017. Rennova Health Provides Outlook for 2017. Jan 5, 2017. Ended Sep 30, 2016. Sign Up for Email Alerts. Be the first to receive breaking news. Jersey City, NJ 07310. 10320 N 56th Street. Tampa, FL 33617.
Renren - INVESTOR RELATIONS - Overview
Started from university campuses in 2005, we now possess a nation-wide penetration with users across all demographics, particularly college students and young white-collar professionals. Our social networking platform serves as the foundation of our business and we aim to build a mobile-centric eco-system that embodies our user needs. As a leader in mobile social networking, we are dedicated in continuing to transform ourselves into a full-fledged mobile technology Company. 160; 0.02. This calendar conta...
RepliCel | Using Cells for Healing
Tel: 604-248-8730 Toll Free: 1-800-248-5255. 4th largest cosmetics company worldwide. Ongoing tendon repair trial. Results expected in 2016. Ongoing skin rejuvenation trial. Results expected in 2016. Our stock trades on the OTCQB. And on the TSX Venture Exchange. TSXV: RP OTCQB: REPCF. Learn more about investing in RepliCel below. SIGN-UP HERE FOR FUTURE UPDATES. HERE’S WHAT INDUSTRY EXPERTS ARE SAYING:. 8220;When I can get potential blue-sky regenerative technologies like. Michael May, Centre for Commer...
Repros Therapeutics Inc. - Investor Relations
Board of Directors and Management. Events, Presentations and Webcasts. Repros in the News. Events, Presentations and Webcasts. Repros in the News. 12:34 PM ET on Jan 12, 2017. Delayed at least 20 minutes. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective. Dec 19, 2016. Dec 12, 2016. View all releases ». 2408 Timberloch Place, B-7.
Investor Relations - RGP
RGP was founded in 1996 within a Big Four accounting firm. Today, we are a publicly traded company with 3,300 professionals, annually serving over 1,700 clients around the world from 68 practice offices. Headquartered in Irvine, California, RGP has served 87 of the Fortune 100 companies. July 16, 2015. Resources Global Professionals Q415 Earnings Conference Call. Resources Global Professionals Announces Quarterly Dividend Payment Date and New Stock Buyback Authorization. To Enhance Resident Safety.
Investor Relations - RGP
RGP was founded in 1996 within a Big Four accounting firm. Today, we are a publicly traded company with 3,300 professionals, annually serving over 1,700 clients around the world from 68 practice offices. Headquartered in Irvine, California, RGP has served 87 of the Fortune 100 companies. July 16, 2015. Resources Global Professionals Q415 Earnings Conference Call. Resources Global Professionals Announces Quarterly Dividend Payment Date and New Stock Buyback Authorization. To Enhance Resident Safety.
Retrophin, Inc. - Investor Relations
Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, San Diego-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), and...
Reunert Limited Integrated Annual report 2013 | Home
2013 ANNUAL INTEGRATED REPORT. How we create value. Material issues and risks. Board and executive management. Chief executive officer’s report. Chief financial officer’s report. Social, ethics and transformation report. Company secretary’s certification. Statements of comprehensive income. Notes to the cash flow statements. Statements of changes in equity. Notes to the annual financial statements. Principal subsidiaries Annexure A. Unconsolidated subsidiary Annexure B. CHIEF EXECUTIVE OFFICER'S REPORT.
Investor Relations | REVA Medical
Skip to main navigation. REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead product, the Fantom bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. ASX RVA.AX (CDI). Mar 30, 2018 12:26 AM EDT. 10 CDIs equivalent to one share of common stock. March 27, 2018. REVA Announces First Implant of Fantom Encore in Switzerland.
SOCIAL ENGAGEMENT